Hamburg Prioritizes Post-Market Safety, Innovation At Confirmation Hearing
This article was originally published in The Gray Sheet
Executive Summary
FDA Commissioner-designate Margaret "Peggy" Hamburg's top priorities for the agency include fostering technological innovation and improving the safety of medical products through closer post-market monitoring
You may also be interested in...
Hamburg clears Senate panel
Margaret Hamburg's nomination to be the next FDA commissioner is endorsed by the Senate Health, Education, Labor and Pensions Committee May 13. The committee action, by voice vote, follows questioning at a hearing May 7 and forwards the nomination to the full Senate, which is expected to vote to confirm her shortly (1"The Gray Sheet" May 11, 2009, p. 4)
Hamburg clears Senate panel
Margaret Hamburg's nomination to be the next FDA commissioner is endorsed by the Senate Health, Education, Labor and Pensions Committee May 13. The committee action, by voice vote, follows questioning at a hearing May 7 and forwards the nomination to the full Senate, which is expected to vote to confirm her shortly (1"The Gray Sheet" May 11, 2009, p. 4)
Push For Rapid Diagnostics, Protective Equipment Amid Flu Outbreak
Government health officials and industry are scrambling to identify and release diagnostics technology that can quickly identify patients stricken with the hybrid flu virus sweeping the globe, while demand for respirators and other personal protective equipment is rising